

INFORME DE BÚSQUEDA DE PATENTES PARA EI RADICADO 14-109690-00000-0000						
CRITERIOS PARA LA BÚSQUEDA						
Palabras clave utilizadas		TTR OR PREALBUMIN dsRNA				
CLASIFICACIONES INTERNACIONALES UTILIZADAS PARA LA BÚSQUEDA						
BASES DE DATOS CONSULTADAS.						
Google patents		Espacenet		The lens		Epoquenet
INFORMES DE EXÁMENES REALIZADOS EN OTRAS OFICINAS						
Oficina	Fecha del examen o de reporte de búsqueda de documentos	Anterioridades encontradas para el examen o reportados en el examen de búsqueda(relacionarlos todos)	Reiv. afectadas	RELEVANCIA (requisito que afecta)	FUERON TENIDOS EN CUENTA PARA EL EXAMEN EN LA OFICINA COLOMBIANA	
					SI	NO
EUROPEA	23/05/2013	US2009239814				X
		US2011237646				X
		WO2011139917				X
		US2011256175				X
		Synthesis, Hybridization, and Nuclease Resistance Properties of 2'-O-Aminooxyethyl (2'-O-AOE) Modified Oligonucleotides. Tetrahedron Letters, 19990122 Pergamon, GB				X
		RNA interference and chemically modified small interfering RNAs. CURRENT OPINION IN CHEMICAL BIOLOGY, 20041201				X
		Lipophilic siRNAs mediate efficient gene silencing in oligodendrocytes with direct CNC delivery. . JOURNAL OF CONTROLLED RELEASE, 20100101 ELSEVIER, AMSTERDAM, NL				X
		Targeted conversion of the transthyretin gene in vitro and in vivo. Gene Therapy, 20040212 Nature Publishing Group, GB				X
		Targeting microRNAs involved in human diseases: A novel approach for				

		modification of gene expression and drug development. Biochemical Pharmacology, 20110805 Elsevier, US				
	11/05/2015	WO2011056883	1-43, 49, 50, 113 y 114	Nivel inventivo	X	
		WO2011056883				X
		WO2010048228				X
		WO2010042877				X
		WO2009073809	1-43, 49, 50, 113 y 114	Nivel inventivo	X	
USPTO	16/09/2015	US9101643				X
		US2013217756				X
		US2009239814				X
		WO2010148013				X
DOCUMENTOS ADICIONALES ENCONTRADOS POR EL EXAMINADOR DE ACUERDO A LOS CRITERIOS DE BÚSQUEDA.						
BÚSQUEDA DE SECUENCIAS						
Número de depósito / patente y N° de secuencia						
% de identidad						
SEQ ID NO (de la solicitud)	NCBI	The Lens	EMBL-EBI	DDJB	Genome Quest	
2208	WO2011056883 SEQ ID No.449					
	100%					
2214	WO2011056883 SEQ ID No. 1347					
	100%					

Criterios de Búsqueda

SEQ ID No. 2214

 Download  [Graphics](#)

WO2013075035_2214

Sequence ID: lcl|Query_258411 Length: 23 Number of Matches: 1

Range 1: 7 to 23 [Graphics](#)

 Next Match  Previous Match

Score	Expect	Identities	Gaps	Strand
34.2 bits(17)	2e-08	17/17(100%)	0/17(0%)	Plus/Plus

Query	1	TACTCTTGTTACATGA	17
Sbjct	7	TACTCTTGTTACATGA	23

[Download](#) [Graphics](#)

WO2011056883_1347

Sequence ID: lcl|Query_28265 Length: 21 Number of Matches: 1

Range 1: 1 to 19 [Graphics](#)

[Next Match](#) [Previous Match](#)

Score	Expect	Identities	Gaps	Strand
38.2 bits(19)	1e-09	19/19(100%)	0/19(0%)	Plus/Plus
Query 4	GAATACTCTTGGTTACATG	22		
Sbjct 1	GAATACTCTTGGTTACATG	19		

SEQ ID No. 2208

[Download](#) [Graphics](#)

WO2013075035_2208

Sequence ID: lcl|Query_108341 Length: 21 Number of Matches: 1

Range 1: 3 to 21 [Graphics](#)

[Next Match](#) [Previous Match](#)

Score	Expect	Identities	Gaps	Strand
38.2 bits(19)	9e-10	19/19(100%)	0/19(0%)	Plus/Plus
Query 1	GTAACCAAGAGTATTCCAT	19		
Sbjct 3	GTAACCAAGAGTATTCCAT	21		

[Download](#) [Graphics](#)

WO2013075035_2208

Sequence ID: lcl|Query_60265 Length: 21 Number of Matches: 1


Range 1: 1 to 17 [Graphics](#)

[Next Match](#) [Previous Match](#)

Score	Expect	Identities	Gaps	Strand
34.2 bits(17)	1e-08	17/17(100%)	0/17(0%)	Plus/Plus
Query 5	ATGTAACCAAGAGTATT	21		
Sbjct 1	ATGTAACCAAGAGTATT	17		

Búsqueda por Epoquenet

EPODOC	1	0	IARN
	2	272	IRNA
	3	736	(TRANSTHYRETIN OR TTR OR PREALBUMIN)
	4	0	2 AND 3
	5	3352	RNAI
	6	13	3 AND 5

1/13 © EPODOC / EPO	
PN	- SG11201402392Q A 20140627
TI	- RNAI AGENTS, COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING TRANSTHYRETIN (TTR) ASSOCIATED DISEASES
2/13 © EPODOC / EPO	
PN	- HK1200171 A1 20150731
TI	- RNAI AGENTS, COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING TRANSTHYRETIN (TTR) ASSOCIATED DISEASES RNAI (TTR)
3/13 © EPODOC / EPO	
PN	- PH12014501106 A1 20140811
TI	- RNAI AGENTS, COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING TRANSTHYRETIN (TTR) ASSOCIATED DISEASES
AB	- The present invention provides RNAI agents, e.g., double stranded RNAI agents, that target the transthyretin (TTR) gene and methods of using such RNAI agents for treating or preventing TTR - associated diseases.
4/13 © EPODOC / EPO	
PN	- MX2014005972 A 20140827
TI	- RNAI AGENTS, COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING TRANSTHYRETIN (TTR) ASSOCIATED DISEASES.
AB	- The present invention provides RNAI agents, e.g., double stranded RNAI agents, that target the transthyretin (TTR) gene and methods of using such RNAI agents for treating or preventing TTR - associated diseases.
5/13 © EPODOC / EPO	
PN	- KR20140092921 A 20140724
TI	- RNAI AGENTS, COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING TRANSTHYRETIN (TTR) ASSOCIATED DISEASES
6/13 © EPODOC / EPO	
PN	- US2014315835 A1 20141023
TI	- RNAI AGENTS, COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING TRANSTHYRETIN (TTR) ASSOCIATED DISEASES
AB	- The present invention provides RNAI agents, e.g., double stranded RNAI agents, that target the transthyretin (TTR) gene and methods of using such RNAI agents for treating or preventing TTR -associated diseases.
7/13 © EPODOC / EPO	
PN	- WO2015042364 A1 20150326
TI	- (A1 AB) METHODS FOR TREATING OR PREVENTING TRANSTHYRETIN (TTR) ASSOCIATED DISEASES
AB	- (A1 AB) The present invention provides methods for treating or preventing transthyretin (TTR-) associated diseases using RNAI agents, e.g., double stranded RNAI agents, that target the transthyretin (TTR) gene.
 FIG. 1	
8/13 © EPODOC / EPO	
PN	- CN104080794 A 20141001
TI	- RNAI agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases
AB	- The present invention provides RNAI agents, e.g., double stranded RNAI agents, that target the transthyretin (TTR) gene and methods of using such RNAI agents for treating or preventing TTR -associated diseases.
9/13 © EPODOC / EPO	
PN	- CA2856243 A1 20130523
TI	- RNAI AGENTS, COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING TRANSTHYRETIN (TTR) ASSOCIATED DISEASES
AB	- The present invention provides RNAI agents, e.g., double stranded RNAI agents, that target the transthyretin (TTR) gene and methods of using such RNAI agents for treating or preventing TTR - associated diseases.
10/13 © EPODOC / EPO	
PN	- AU2012340159 A1 20140522
TI	- RNAI agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases
AB	- The present invention provides RNAI agents, e.g., double stranded RNAI agents, that target the transthyretin (TTR) gene and methods of using such RNAI agents for treating or preventing TTR - associated diseases.
11/13 © EPODOC / EPO	
PN	- EP2780393 A1 20140924
TI	- (A1 AB) RNAI AGENTS, COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING TRANSTHYRETIN (TTR) ASSOCIATED DISEASES
12/13 © EPODOC / EPO	
PN	- WO2013075085 A1 20130523
TI	- RNAI AGENTS, COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING TRANSTHYRETIN (TTR) ASSOCIATED DISEASES
AB	- The present invention provides RNAI agents, e.g., double stranded RNAI agents, that target the transthyretin (TTR) gene and methods of using such RNAI agents for treating or preventing TTR - associated diseases.
13/13 © EPODOC / EPO	
PN	- CN102206643 A 20111005
TI	- (A B) Mediating method of RNAI (ribonucleic acid interference) utilizing lentiviral vector
AB	- (A) The present invention relates to a mediating method of RNAI (ribonucleic acid interference) utilizing a lentiviral vector. The method comprises the following specific steps of: firstly carrying out homology analysis on the nucleic acid sequence of relevant viruses to find out conserved regions and designing siRNA (small interfering ribonucleic acid) corresponding to the conserved regions of the related viruses; and cloning the siRNA to an expression plasmid pLVTH, then co-transfecting 293T cells together with pCMV-dR8.91 and pMD2.G, collecting the supernatant of the transfected cells, carrying out ultracentrifugation, purification and concentration to obtain a high-titer lentiviral vector expressing the siRNA, then carrying out cotransduction into target cells together with LV- 4TR -KRAB, and strictly controlling the acting time and dose of siRNA drugs utilizing tetracycline analogue DOX. Because of high transduction rate and a stringent control system, the mediating method can actually evaluate the in-vivo antiviral action of the siRNA and can track the whole process of drug interference action, thus having clinical application prospects.

NPL	1	936 (TRANSTHYRETIN OR TTR OR PREALBUMIN)
	2	1661 RNAI
	3	4 1 AND 2

1/4 © NPL / EPO	
AN	- XP029207353
TI	- A PHASE 2, MULTI-CENTER, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS AND EXPLORATORY CLINICAL ACTIVITY OF ALN-TTRSC, AN RNAI THERAPEUTIC FOR THE TREATMENT OF PATIENTS WITH TRANSTHYRETIN CARDIAC AMYLOIDOSIS
DT	- Journal Article
AU	- Gilmore Julian David; Falk Rodney; Maurer Mathew; Hanna Maazen; Karsten Verena; Penz Craig; Zimmermann Tracy; Gollöb Jared; Hawkins Philip
PUB	- JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY - ELSEVIER, NEW YORK, NY, US
VOL	- 65
NR	- 10
LNKD	- doi:10.1016/S0735-1097(15)60971-8
2/4 © NPL / EPO	
AN	- XP055175697
TI	- 866.S/W1: ALN-TTR, an RNAI therapeutic for the treatment of transthyretin -mediated amyloidosis
DT	- Conference Proceedings Article
AU	- Chen Borland T Q; Wang G; Akinc A; Nechev I; Kosovrasti V; Tchangov I; Costelha S; Saraiva M; Sah D; Alvarez R
PUB	- Abstracts of the Annual Meeting of the Society for Neuroscience; 40th Annual Meeting of the Society-for-Neuroscience, - 20100101; 20101113 - 20101117 - SOCIETY FOR NEUROSCIENCE, WASHINGTON, DC, US; San Diego, CA, USA
VOL	- 40
PG	- 866.S/W1
PD	- 2010-01-01
ORD	- 2010-00-00

3/4 © NPL / EPO	
AN	- XP055175694
TI	- 802: ALN- TTR , AN RNAI THERAPEUTIC FOR THE TREATMENT OF TRANSTHYRETIN AMYLOIDOSIS
DT	- Conference Proceedings Article
AU	- Sah Dinak Chen Qingmin W Y; Costelha Suzette; Butler Jim; Fishman Shannon; Rossomando Anthony; Nechev Lubomir; Saraiva Maria Joao; Coelho Teresa; Suhr Ole B; Adams David; Lozeron Pierre; Hawkins Philip; Mant Timothy; Hutabarat Renta; Falzone Rick; Cehelsky Jeff; Figueroa Yaysie; Vaishnav Akshay; Gollob Jared
PUB	- Nucleic Acid Therapeutics; 7th Annual Meeting of the Oligonucleotide-Therapeutics-Society, - 20111017; 20110908 - 20110910 - Mary Ann Liebert, Inc. Publishers, US; Copenhagen, DENMARK
VOL	- 21
NR	- 5
PG	- A55 - A56
PD	- 2011-10-17
ORD	- 2011-10-03
LNKD	- doi-10.1089/nat.2011.1502
4/4 © NPL / EPO	
AN	- XP055163313
TI	- Safety and Efficacy of RNAI Therapy for Transthyretin Amyloidosis
DT	- Journal Article
AU	- Teresa Coelho; David Adams; Ana Silva; Pierre Lozeron; Philip N Hawkins; Timothy Mant; Javier Perez; Joseph Chiesa; Steve Warrington; Elizabeth Tranter; Malathy Munisamy; Rick Falzone; Jamie Harrop; Jeffrey Cehelsky; Brian R Bettencourt; Mary Geissler; James S Butler; Alfica Sehgal; Rachel E Meyers; Qingmin Chen; Todd Borland; Renta M Hutabarat; Valerie A Clausen; Rene Alvarez; Kevin Fitzgerald; Christina Gamba-Vitalo; Saraswathy V Nochur; Akshay K Vaishnav; Dinah W Y Sah; Jared A Gollob; Ole B Suhr
PUB	- New England Journal of Medicine, - 20130829 - New England Journal of Medicine
VOL	- 369
NR	- 9
PG	- 819 - 829
PD	- 2013-08-29
ORD	- 2013-08-29
LNKD	- doi-10.1056/NEJMoa1208760